Kissei Pharmaceutical Co., Ltd. (TYO:4547)

Market Cap	192.75B +16.7%
Revenue (ttm)	95.29B +14.3%
Net Income	14.14B +21.2%
EPS	337.35 +27.2%
Shares Out	41.45M
PE Ratio	13.78
Forward PE	15.45
Dividend	120.00 (2.59%)
Ex-Dividend Date	Mar 30, 2026

Volume	60,500
Average Volume	73,170
Open	4,600.00
Previous Close	4,630.00
Day's Range	4,570.00 - 4,650.00
52-Week Range	3,480.00 - 4,815.00
Beta	-0.26
RSI	50.02
Earnings Date	Jan 30, 2026

About Kissei Pharmaceutical

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of rena...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1946
• Employees: 1,778
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4547

Financial Performance

In fiscal year 2025, Kissei Pharmaceutical's revenue was 88.33 billion, an increase of 16.87% compared to the previous year's 75.58 billion. Earnings were 11.96 billion, an increase of 7.18%.